OxyPAP from D-R Burton Healthcare

The OxyPAP features a breakthrough in hygiene, a critical need for respiratory patients at risk for infection, because the OxyPAP’s convenient handle converts to a hygienic mouthpiece cover when not in use.

FARMVILLE, N.C. (PRWEB)
March 02, 2020

D•R Burton Healthcare Products LLC presents the OxyPAP™ Positive Airway Pressure (PAP) device delivering oxygen flow with unique hygiene protection for patients needing lung expansion therapy. The OxyPAP uniquely can be used with other D•R Burton products to deliver oxygen flow for patients needing secretion clearance during Oscillating Positive Expiratory Pressure (OPEP) therapy.

“The OxyPAP features a breakthrough in hygiene, a critical need for respiratory patients at risk for infection” according to Dennis Cook, BSRT, RRT, CEO of D•R Burton, because the OxyPAP’s convenient handle converts to a hygienic mouthpiece cover when not in use. The OxyPAP is used to help patients expand their lungs and also delivers supplemental oxygen especially useful for patients who cannot take a deep breath during respiratory therapy.

Besides providing lung expansion and oxygen flow for patients via PAP therapy, the OxyPAP can also help patients clear secretions by working in conjunction with other D•R Burton OPEP devices. According to Cook, “the component design of the OxyPAP allows clinicians to tailor effective respiratory therapy to individual patient needs while providing economic value to healthcare providers.

About D•R Burton Healthcare Products LLC

D•R Burton Healthcare Products LLC, innovators in medical devices, was founded by clinicians with deep expertise in respiratory care and anesthesia. Together we design, develop and market medical device products that allow patients to heal faster and provide value to our partners and consumers. Our unique clinical perspective drives our unwavering commitment to provide clinicians and their patients with a world class user experience. For more information, please visit http://www.drburtonhpi.com

Share article on social media or email:

Raising awareness of this epidemic is important to the work of physicians across CVR. Chronic venous insufficiency, or vein disease, is more likely in patients that have had a DVT, and DVTs are one possible side effect of late stage vein disease.

GREENBELT, Md. (PRWEB)
March 02, 2020

For the sixth year in a row, Center for Vein Restoration (CVR) will be participating in national Deep Vein Thrombosis (DVT) Awareness Month. According to the American Heart Association, over 2.5 million Americans are affected by DVT annually, with over 600,000 people hospitalized each year. DVT, with its risk of pulmonary embolism, may be the most preventable cause of death among people hospitalized today in the United States. Despite its prevalence, many Americans are still unaware of the threat DVTs pose to their health.

Raising awareness of this epidemic is important to the work of physicians across CVR. Chronic venous insufficiency, or vein disease, is more likely in patients that have had a DVT, and DVTs are one possible side effect of late stage vein disease. The initial symptoms and risk factors for each condition are also similar. Early detection of DVTs is essential for successful treatment, and the vein disease screenings provided to each CVR patient can help identify DVTs.

Everyday, in its 84 practices across the nation, CVR provides DVT rule-out ultrasounds to patients referred by physicians who suspect a DVT but want to save their patients a costly, long, and stressful trip to the emergency room. CVR can also provide an immediate treatment plan for the DVT, or additional screening for vein disease, if needed.

CVR physicians educate about DVTs as a possible side effect of vein disease year-round. As part of CVR’s re-commitment to DVT Awareness Month in 2020, the company will be:

• Distributing printed resources and magnets on DVT Symptoms and Risk Factors and a guide on DVT and Orthopedic Surgery to doctors’ offices nationwide
• Focusing content on the urgency of DVTs in CVR blogs, commercials, interviews, and print ads
• Rolling out a social media awareness campaign centered around the signs, symptoms and risk factors of DVTs and the connection to vein disease

Dr. Khanh Q. Nguyen, the Chief Medical Officer at CVR, is proud to lead CVR’s DVT Program. “Since 2014, we’ve managed over 3,000 DVT patients in the outpatient setting safely,” says Dr. Nguyen. “We are committed to providing state of the art venous care and complete DVT management while maintaining close communication with the referring physician.”

DVT Awareness Month was established in 2003 and sponsored by the Coalition to Prevent Deep-Vein Thrombosis. March is officially recognized as Deep-Vein Thrombosis (DVT) Awareness Month by United States Senate Resolution 56.

For more on CVR’s awareness campaign, follow:

ABOUT DEEP VEIN THROMBOSIS

A Deep Vein Thrombosis (DVT) is a dangerous blood clot that can form in the leg veins, or in other places in the body. The clot can be dislodged and move to other veins and arties, causing heart attack, stroke or plumonary embolism. Clots form when circulation is hindered by thick blood, genetic or hormonal factors, slow blood flow, inactivity or damaged veins. DVTs are most common in adults over age 60, but can occur at any age. Blood is more likely to clot, and vein valves are more likely to fail, for moms and pregnant women, smokers, long-distance travelers and those taking birth control pills, among other risk factors.

ABOUT VENOUS INSUFFICIENCY

Venous insufficiency, the cause of significant suffering due to the sequelae of venous hypertension, most commonly arises as achy, tired and heavy legs. It may or may not be associated with varicose veins, spider veins or skin changes including venous ulcerations and indiscriminately affects between 30–40 million Americans. Numerous factors including age, weight, prolonged sitting or standing, genetics or a history of DVT (blood clots) can increase the risk of developing this common and often underdiagnosed disorder. Treatment options have evolved to an array of minimally invasive procedures in an office setting.

ABOUT CENTER FOR VEIN RESTORATION

Center for Vein Restoration (CVR) is the largest physician-led practice treating vein disease in the country. Having performed its first procedure in 2007 under President and CEO Dr. Sanjiv Lakhanpal, Center for Vein Restoration has since become nationally recognized as the clinical leader in treating chronic venous insufficiency. With 84 centers and growing, CVR has over 500 employees and conducts over 200,000 patient interactions annually. To learn more about CVR and its mission, visit http://www.centerforvein.com or by phone at 1-800-FIX-LEGS.

Share article on social media or email:

Décor Series Camtrays trays are ideal for operations ranging from high-traffic foodservice establishments to healthcare settings.

HUNTINGTON BEACH, Calif. (PRWEB)
March 02, 2020

The newest Camtray by Cambro Manufacturing is a modern, durable and functional piece that will elevate the look of your operation. The Décor Series Camtrays are designed to appear and feel like authentic wood while actually being made of a durable fiberglass material. These Camtrays convey a modern-rustic vibe while providing the long-lasting durability of the classic Camtray.

Décor Series Camtrays can be made with a standard woodgrain textured surface or with Cambro’s clear non-skid surface called EpicTread™. EpicTread provides safer handling, a reduction in accidental spills and the elimination of tray mats. Decrease on-going costs while reducing waste when choosing an EpicTread surface. Décor Series Camtrays trays are ideal for operations ranging from high-traffic foodservice establishments to healthcare settings.

Choose from three tray sizes and five colors of woodgrain; personalization is also available. Promote the branding of your business by personalizing the front, back or both with a full-color logo or design.

Décor Series Camtrays are scratch, chip, break, stain and chemical resistant, in addition to coming with a five-year prorated warranty. Both surface textures are safe for use in high temperature dishwashers.

About Cambro Manufacturing

Cambro Manufacturing is a leading manufacturer and distributor of equipment and products to the foodservice industry worldwide. Brothers William and Argyle Campbell founded Cambro in 1951 with a small factory in Huntington Beach, Calif. More than 60 years later, Cambro is still a family-owned and privately held company committed to innovation, quality and value. More information on Cambro is available at http://www.cambro.com.

Share article on social media or email:

Cas-CLOVER – the best of both CRISPR/Cas9 and TALEN gene editing

“High fidelity editing is extremely important to us and our partners as off-targets can effect important characteristics…

LEXINGTON, Ky. (PRWEB)
February 26, 2020

Announcement Key Points:

Hera and Demeetra stem from the gene editing platforms company Transposagen (now a Hera BioLabs company) which is best known for its commercialization of the piggyBac® transposase

Cas-CLOVER differs from single-guided CRISPR and dual-guided CRISPR nickase systems as it is truly dimeric and demonstrates high fidelity with no detectable off-targets while maintaining robust editing efficiency

Issued patents cover these technologies enabling clear freedom-to-operate

Evaluation opportunities and services for Cas-CLOVER which can convert into full research and commercial licenses with very accessible terms are available

Demeetra is operating in the pharmaceutical/industrial bioprocessing space as well as agricultural biotechnology, while Hera is focused on products tools and services for research and drug discovery

Targeted nuclease gene editing is a powerful tool for accelerating and improving opportunities for successful drug and cell therapy development from target identification and candidate selection through the production of GMP biologics. And has been used successfully to engineer T-cell therapies. Technologies such as ZFNs, CRISPR/Cas9 and now Cas-CLOVER bind to the target DNA and generate insertions and deletions (“indels”) resulting in “knockout” mutations or targeted “knock-ins” when supplied with the appropriate guide RNA(s) and donor vector.

CRISPR/Cas9 was a breakthrough for gene editing since it offers a simple and cost-effective method for high efficiency modification of the desired target locus. CRISPR does have a known trade-off as the technology demonstrates high degrees of off target mutagenesis, modifying the genome at undesired locations, in addition to the gene of interest. Off-target mutagenesis also occurs with the dual guided CRISPR nickase system which has been characterized as not truly dimeric (1, 2). Furthermore, licensing restrictions or lack of clear commercial freedom to operate have limited CRISPR/Cas9 use commercially.

Unlike CRISPR/Cas9, which is a monomeric nuclease targeted by a single guide RNA, Cas-CLOVER is a dimeric nuclease system targeted by 2 guide RNAs and has no detectable off-target mutations (3).

The Cas-CLOVER dimeric system uses two guide RNAs targeting “half-site” sequences. The two half-sites are separated by a spacer region where genomic DNA is cleaved with the proprietary dimeric Clo51 nuclease. The stringency of the dimeric Clo51 nuclease gives it the specificity that has shown no off-target activity after millions of next generation sequencing (NGS) reads in human T-cells. Guide RNA design for any gene of interest is flexible, as the spacer region between the guides is ideally between 16-30 bases (4).

“High fidelity editing is extremely important to us and our partners as off-targets can effect important characteristics such as growth rate and cloning efficiency in bioprocessing systems” said Jack Crawford CEO of Demeetra. Demeetra and Hera recently collaborated to validate Cas-CLOVER in Chinese hamster ovary (CHO) cell lines for bioprocessing. “Cas-CLOVER is a perfect fit for us as we move into crop trait engineering where we want to minimize off-target risks and reduce timelines due to backcrossing which is required with traditional chemical mutagenesis” he added.

Hera’s SRG OncoRat® is another example of nuclease applications. The Sprague Dawley strain was engineered to contain a knockout in both the Rag2 and IL2rg genes resulting in a fully immunodeficient rat. Dozens of human tumor models have been validated in the OncoRat, including a prostate cancer model recently published in a top tier drug development journal (5).

“Cell and gene therapy research may especially benefit from Cas-CLOVER where off-target mutagenesis is unacceptable” added Mike Schlosser the CEO of Hera. Both proliferating and resting human T-cells have been successfully targeted by Cas-CLOVER to remove cell surface markers associated with graft versus host disease (GVHD) (4).

About Hera

Hera Biolabs, Inc., based in Lexington, KY is an innovative preclinical contract services, products and licensing company. Our mission is to use cutting-edge gene-editing technologies to accelerate preclinical research and drug and cell-based therapeutic discovery and development. Hera built the SRG platform, an immunocompromised double knockout Sprague-Dawley rat engineered for T-cell, B-cell, and NK cell deficiency. Our first established commercial model is the SRG OncoRat, a valuable complement or alternative to oncology studies in mice, and well suited for xenograft oncology studies given its excellent tumor take-rates, large tumor mass, and smooth transition from efficacy to safety. Hera sells the SRG OncoRat to researchers and has been conducting oncology/pharmacology studies for clients over the past 5 years. Using immunocompromised husbandry procedures, our experienced staff performs studies in our on-site state-of-the-art vivarium that features dual HEPA-filtered, disposable IVC rodent caging systems. We’re also continuing to use our proprietary Cas-CLOVER CRISPR system and piggyBac gene-editing technologies and know-how to expand our robust pipeline of models and services.

About Demeetra

Demeetra AgBio is “Engineering Traits for Life” by introducing gene editing technologies in the agriculture, industrial, pharmaceutical & animal health industries. We provide licenses for Cas-CLOVER (the clean CRISPR/Cas9 alternative) and piggyBac transposase or partner under joint development agreements for applications in the engineering of crops and agricultural animals, plant-based drug development and enhanced bioprocessing in human & animal health.

References

1.    Tsai et al. (2014) Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nature Biotechnology.

2.    Lee et al (2015) Site-specific integration in CHO cells mediated by CRISPR/Cas9 and homology-directed DNA repair pathway. Scientific Reports

3.    Li et al (2018) Cas-CLOVER™: A High-Fidelity Genome Editing System for Safe and Efficient Modification of Cells for Immunotherapy. Precision CRISPR Congress Poster.

4.    Wang et al. (2017) Genome Editing of Therapeutic CAR-T Cells Using A Novel Clo51-dCas9 (NextGEN™) CRISPR System. American Society for Cell & Gene Therapy Poster.

5.    Ponnusamy (2019) Orally -Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research

Share article on social media or email: